Trump Announces Price Deals With Eli Lilly and Novo Nordisk, Cutting Ozempic and Wegovy to $350 a Month Through TrumpRx
On November 6, 2025, President Donald J. Trump announced in Washington that the federal government had reached agreements with Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for several widely used prescription drugs. The White House said the agreements cover the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease, obesity and other conditions.
Under the agreements, the prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through the government platform TrumpRx. The price of Zepbound, and of Eli Lilly's oral drug orforglipron if approved, will fall from $1,086 per month to an average of $346 through TrumpRx. If the Food and Drug Administration later approves the Wegovy pill or similar oral GLP-1 drugs, the initial dose of those drugs will be priced at $150 per month through TrumpRx.
Under Medicare, the prices of Ozempic, Wegovy, Mounjaro and Zepbound will be $245, with beneficiaries paying a co-pay of $50 per month, and state Medicaid programs will also have access to these medications at these prices. The White House said the lower prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.
The agreements also cut prices for other medicines from the two companies: Eli Lilly's migraine treatment Emgality at $299 per pen, its diabetes medicine Trulicity at $389 per month, and Novo Nordisk insulin products including NovoLog and Tresiba at $35 per month of supply. Both companies will guarantee most-favored-nation prices on new medicines they bring to market and expand investment in the United States: Novo Nordisk committed an additional $10 billion to strengthen its domestic footprint, and Eli Lilly has announced at least $27 billion in new U.S. manufacturing investments under President Trump.
The White House said the Centers for Disease Control and Prevention estimates the prevalence of obesity among American adults to be 40 percent. On May 12, 2025, President Trump signed an executive order directing that American drug prices be brought in line with those paid by similar nations, and on July 31 he sent letters to leading manufacturers setting out the steps required. Since September 30, 2025, the administration has announced five such deals with major pharmaceutical manufacturers.
Source: The White House
Published by GSM · USA (original Chinese edition)
Photo: 图：位于华盛顿的美国卫生与公众服务部总部休伯特·汉弗莱大楼（资料照片）。ajay_suresh摄，CC BY 2.0，经Wikimedia Commons；联邦固定图库同源图。 / Photo: The Hubert H. Humphrey Building, headquarters of the U.S. Department of Health and Human Services in Washington (file photo). By ajay_suresh, CC BY 2.0, via Wikimedia Commons; federal fixed image library image.
